RESUMEN
â¢Mexican individuals received via telehealth the unified protocol for anxiety, depression, and trauma related disorders.â¢Online unified protocol reduced depression, anxiety, emotional issues, uncertainty intolerance, and psychological distress.â¢The transdiagnostic unified protocol is well-suited to train therapists for emotional, trauma, and stressor-related disorders.
RESUMEN
The current systematic review sought to identify quantitative empirical studies that focused on the transdiagnostic factors of intolerance of uncertainty, emotional dysregulation and rumination, and their relation with depression and post-traumatic stress disorder (PTSD). The overall research aim was to examine the relationship between these transdiagnostic factors and their relation with depression and PTSD symptoms. The systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines. Out of the 768 articles initially identified, 55 met the inclusion criteria for the current review. The results determined that intolerance of uncertainty is indirectly related to depression and PTSD symptoms, mainly through other factors including emotion dysregulation and rumination. Additionally, emotional dysregulation is a significant predictor of both depression and PTSD symptoms. Rumination is a robust factor related to depression and PTSD symptoms, this relationship was significant in cross-sectional and longitudinal studies. This review provides evidence on the transdiagnostic factors of intolerance of uncertainty, emotional dysregulation and rumination in the relationship with depression and PTSD symptoms.
RESUMEN
ABSTRACT Background: The Intolerance of Uncertainty Scale short version (IUS-12) has proven to be a robust self-report measure to assess intolerance of uncertainty. While previous psychometric analyses of the IUS-12 have established a stable two-factor structure corresponding to the prospective and inhibitory factors of intolerance of uncertainty, recent studies suggest that the bifactor model may better explain its factor structure. Objective: The aim of the current study was to culturally adapt and validate the IUS-12 in a Mexican population. Method: The aim of the current study was to culturally adapt and validate the IUS-12 in a Mexican population. Result: Confirmatory factor analyses supported a bifactor model and a good internal consistency. Invariance testing indicated partial invariance across women and men. Convergent validity tests showed that the IUS-12 was related to measures of worry, as well as depression and anxiety. Conclusion: These findings provide evidence for the reliability and validity of the adapted version of the IUS-12 in Mexico.
RESUMEN Introducción: La Escala de Intolerancia a la Incertidumbre versión corta (IUS-12) ha demostrado ser una medida robusta de autoinforme para evaluar la intolerancia a la incertidumbre. A pesar de que los análisis psicométricos anteriores de la IUS-12 han establecido una estructura de dos factores correlacionados que corresponde a los factores prospectivo e inhibitorio de la intolerancia a la incertidumbre, estudios recientes sugieren que el modelo bifactorial puede explicar mejor su estructura factorial. Objetivo: El objetivo del estudio actual fue adaptar culturalmente y validar la IUS-12 para su uso en la población mexicana. Método: El estudio se llevó a cabo con una muestra comunitaria no probabilística por conveniencia de 405 adultos con edades comprendidas entre los 18 y 70 años. Resultados: Los análisis factoriales confirmatorios respaldaron un modelo bifactor y una buena consistencia interna. Las pruebas de invarianza indicaron invarianza parcial entre mujeres y hombres. Las pruebas de validez convergente mostraron que la IUS-12 estaba relacionada con medidas de preocupación, así como con depresión y ansiedad. Conclusión: Estos hallazgos proporcionan evidencia de la fiabilidad y validez de la versión adaptada de la IUS-12 en México.
RESUMEN
BACKGROUND: Emotional and stress-related disorders show high incidence, prevalence, morbidity, and comorbidity rates in Mexico. In recent decades, research findings indicate that cognitive behavioral interventions, from a disorder-specific perspective, are the effective front-line treatment for anxiety and depression care. However, these treatments are not often used. Reasons include limited access and low availability to effective interventions and comorbidity between mental disorders. Emotional deregulation of negative affectivity has been found to be a mediating factor in addressing emotional disorders from a transdiagnostic perspective, aimed at two or more specific disorders. In addition, technological advancement has created alternatives for psychological assistance, highlighting the possibilities offered by technologies since Internet-supported intervention programs have been empirically tested for effectiveness, efficiency and efficacy and can be key to ensuring access to those who are inaccessible. The aim of the study is to evaluate the efficacy, moderators of clinical change and acceptability of a transdiagnostic guided Internet-delivered intervention versus a transdiagnostic self-guided Internet-delivered intervention for emotional, trauma and stress-related disorders, and waiting list in community sample. METHODS: A three-armed, parallel group, superiority randomized controlled clinical trial with repeated measurements at four times: pretest, posttest, follow-up at 3, 6 and 12 months. Outcomes assessor, participant, care provider and investigator will be blinded. Participants aged 18 to 70 years will be randomly allocated 1:1:1 to one of three study arms: a) Transdiagnostic guided internet-delivered intervention with synchronous assistance, b) Transdiagnostic self-guided internet-delivered intervention, c) Waiting list group. Based on sample size estimation, a minimum of 207 participants (69 in each intervention group) will be included. DISCUSSION: The study could contribute to improving the efficacy of transdiagnostic internet-delivered interventions to promote the dissemination of evidence-based treatments and eventually, to decrease the high prevalence of emotional and trauma-related disorders in the Mexican population. TRIAL REGISTRATION: ClinicalTrial.gov: NCT05225701 . Registered February 4, 2022.
